RARE peer analysis
Ultragenyx (RARE) against its competitors: price, today's move, 1-year return and market value side by side.
RARE and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ABEO Abeona Therapeutics | $4.35 | -4.61% | -14.37% | $248.75M |
| BBIO BridgeBio Pharma | $74.97 | 0.02% | 18.30% | $14.60B |
| BMRN BioMarin | $53.67 | -8.27% | 3.39% | $11.33B |
| FDMT 4D Molecular | $11.35 | -4.62% | 0.27% | – |
| MGTX MeiraGTx | $9.49 | -2.22% | 8.71% | $911.45M |
| MREO Mereo BioPharma | $0.29 | -4.08% | -84.68% | $46.23M |
| PTCT PTC Therapeutics | $60.84 | 1.45% | -10.67% | $5.01B |
| QURE uniQure | $22.97 | -7.49% | -66.15% | $1.72B |
| RCKT Rocket Pharmaceuticals | $2.44 | -3.94% | -34.05% | $267.85M |
| RGNX REGENXBIO | $7.20 | -2.83% | -43.84% | $475.29M |
| RARE Ultragenyx | $16.32 | 1.37% | -53.60% | $1.59B |
- RARE's peers: ABEO (Abeona Therapeutics), BBIO (BridgeBio Pharma), BMRN (BioMarin), FDMT (4D Molecular), MGTX (MeiraGTx), MREO (Mereo BioPharma), PTCT (PTC Therapeutics), QURE (uniQure).
Updated 2026-11-02 23:13 UTC